Selected
Type of publications
Regions
Countries
Diseases
Methodological quality (AMSTAR 2)
60 results found
2024 ∙ Alalawi, M. Alsalloum, M. A. Garwan, Y. M. Abuzeid, M. Alalawi, H. Eljaaly, K. Thabit, A. K. Jose, J.
COVID-19 vaccine hesitancy among healthcare workers in Arab Countries: A systematic review and meta-analysis
  • Healthcare workers
  • COVID-19
  • Acceptance
  • Coverage
Rating:
Not applicable
2023 ∙ Sadat Larijani, M. Doroud, D. Banifazl, M. Karami, A. Bavand, A. Ashrafian, F. Ramezani, A.
A landscape on disorders following different COVID-19 vaccination: a systematic review of Iranian case reports
  • All age groups
  • Islamic Republic of Iran
  • COVID-19
  • Safety
Rating:
Critically low
2023 ∙ Alhandod, T. A. Rabbani, S. I. Almuqbil, M. Alshehri, S. Hussain, S. A. Alomar, N. F. Mir, M. A. Asdaq, S. M. B.
A Systematic Review on the Safety and Efficacy of COVID-19 Vaccines Approved in Saudi Arabia
  • Adults
  • Older adults
  • Saudi Arabia
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Rating:
Critically low
2023 ∙ Liu, Y. Kuang, K.
Predictors of COVID-19 vaccination hesitancy in China: a meta-analysis
  • All age groups
  • China
  • COVID-19
  • Acceptance
Rating:
Not applicable
2023 ∙ Middleton, Bianca F. Danchin, Margie Fathima, Parveen Bines, Julie E. Macartney, Kristine Snelling, Thomas L.
Review of the health impact of the oral rotavirus vaccine program in children under 5 years in Australia: 2006 - 2021
  • Newborn
  • Children
  • Australia
  • Rotavirus
  • Coverage
  • Efficacy/effectiveness
  • Safety
Rating:
Critically low
2023 ∙ Aldali, J. A. Abutheeb, A. Al-Fahd, A. Alzakari, M. Almukhalafi, O. Al-Tayar, N. Almeziny, A. Anwer, R.
The Most Common Side Effects of AstraZeneca COVID-19 Vaccine among Saudi Arabian Population: A Systematic Review
  • All age groups
  • Saudi Arabia
  • COVID-19
  • Safety
Rating:
Critically low
2023 ∙ Iqbal, M. S. Khan, S. U. Qamer, S. Vohra, S.
Vaccine Hesitancy of COVID-19 among Parents for Their Children in Middle Eastern Countries-A Systematic Review
  • Parents/caregivers
  • COVID-19
  • Acceptance
Rating:
Not applicable
2023 ∙ ATAGI
ATAGI recommendations on use of the Moderna and Pfizer monovalent Omicron XBB.1.5 COVID-19 vaccines
  • Recommendation
  • Australia
  • COVID-19
Download:
2023 ∙ ATAGI
ATAGI Update on the COVID-19 Vaccination Program
  • Recommendation
  • Australia
  • COVID-19
Download:
2023 ∙ ATAGI
ATAGI advice on the preferential use of bivalent COVID-19 vaccines for primary vaccination of people aged 12 years or older
  • Recommendation
  • Australia
  • COVID-19
Download: